Gastroesophageal Cancer

2019 GI Cancers Symposium: Pembrolizumab in Second-Line Therapy for Advanced Esophageal Cancer

Pembrolizumab significantly improved overall survival in the second-line setting of advanced esophageal cancer in patients whose tumors tested positive...

Gastrointestinal Cancer

2019 GI Cancers Symposium: Safety, Efficacy of Trifluridine/Tipiracil in Metastatic Gastric Cancer With or Without Gastrectomy

In a poster session, David Ilson, MD, of Memorial Sloan Kettering Cancer Center, and colleagues reported on a preplanned subgroup analysis of the double-blind phase III TAGS study...

Pancreatic Cancer

2019 GI Cancers Symposium: Neoadjuvant Chemotherapy vs Upfront Surgery in Resectable Pancreatic Cancer

A phase II/III trial presented by Unno et al sought to compare neoadjuvant chemotherapy to upfront surgery in patients with histologic confirmation...

Colorectal Cancer

2019 GI Cancers Symposium: Durvalumab, Tremelimumab, and Best Supportive Care vs Best Supportive Care Alone in Advanced, Refractory Colorectal Cancer

The phase II CCTG CO.26 trial evaluated whether the combination of durvalumab, a programmed cell death ligand 1 (PD-L1) inhibitor...

Hepatobiliary Cancer

2019 GI Cancers Symposium: Nivolumab vs Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma

Anti–programmed cell death protein 1 and anti–cytotoxic T-lymphocyte–associated protein 4 antibodies have shown activity in hepatocellular carcinoma...



More Top Stories

Palliative Care
Pain Management

Leslie J. Blackhall, MD, on Unregulated Opioid Access: Consequences and Outcomes

Issues in Oncology

Immunotherapy-Related Toxicities May Be More Common Than Originally Reported

Immunotherapy has significantly improved the overall survival of patients with non–small cell lung cancer (NSCLC) and is generally better tolerated than traditional chemotherapies, but the results of a retrospective study suggested that immunotherapy side effects may be more common than initially...


Breast Cancer Surveillance Consortium Analysis of Trends in Breast Density Assessment

In a study reported in the Journal of the National Cancer Institute, Sprague et al found that only small changes in the proportions of women found to have dense breasts on digital mammography have occurred with revisions in Breast Imaging Reporting and Data System (BI-RADS) density classification...


Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial

Supportive Care
Palliative Care

Improving Palliative Care in Low-Resource Settings

In 2016, ASCO published an update to its Clinical Practice Guideline, “Integration of Palliative Care Into Standard Oncology Care,” which provides evidence-based recommendations for symptom management, clarification of treatment goals, support of coping and distress management, and coordination of...

Nicholas J. Petrelli, MD, FACS, Receives Commendation for Excellence Award From Christiana Care Health System

Nicholas J. Petrelli, MD, FACS, Bank of America Endowed Medical Director of the Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute in Newark, Delaware, recently received the Annual Commendation for Excellence from Christiana Care’s Medical-Dental Staff. An expert ...

Analysis of Proportion of Cancer Cases Attributable to Excess Body Weight Across U.S. States

In a study reported in JAMA Oncology, Islami et al assessed the population attributable fraction (PAF)—the proportion of a given outcome attributable to a given risk factor—of incident cancer cases associated with excess body weight among individual U.S. states during 2011 to 2015. The...

Breast Cancer

Monica Morrow, MD, on View From the Trenches: What Will You do on Monday Morning?

Lung Cancer

New Data Reported From International Studies of Lung Cancer Treatment

At the European Society for Medical Oncology (ESMO) 2018 Congress, important studies were presented for every cancer type. Here, The ASCO Post offers some snapshots of lung cancer studies that may inform approaches to treating this common cancer, which—despite the advances in recent years—remains...


Study Finds High Tumor Mutational Load Is a Predictor of Response to Immunotherapy in Some Cancers

Although the emergence of immune checkpoint inhibitors over the last decade has revolutionized the treatment of patients with metastatic cancers, only a minority of patients experience long-lasting benefit from the therapy. A study investigating the association between tumor mutational burden and...